Our Product
The very first at-home, noninvasive rapid test for endometriosis.
Welcome to Endosense
Say goodbye to lab work, invasive surgeries, and expensive, time-consuming processes. Consisting of one multiplexed lateral flow assay for proteins and another multiplexed nucleic acid biosensor for microRNAs, EndoSense innovates and optimizes to tackle diagnostic delays devastating women’s quality of life. Made to be cheap, fast, convenient, accessible, and accurate, EndoSense is everything that quality healthcare should stand for; making women’s health make sense, one diagnosis at a time.
Paired with a cloud-based app that includes an AI algorithm, EndoSense uses machine learning to quantitatively analyze test results, allowing users to obtain a diagnosis in less than 20 minutes, with 25% greater accuracy than human readers, all entirely at-home. The app also has built in tracking functions for symptoms, medications, diet, exercise, and more – customizable to create the best, personalized management plan.
Built with Multiplexed Lateral Flow Technology
Multiplexed with a panel of proteins – CA-125, CCR1, and MCP-1 – and a panel of microRNAs – miR‐199a, miR‐122, miR‐145, and miR‐542‐3p, the unique multiline, sandwiched lateral flow design allows for the comprehensive detection of multiple biomarkers simultaneously, increasing precision and accounting for various presentations and stages of the disease.